A new vaccine has been developed that can be used to protect against the coronave virus.
The company behind it says it has been approved for use in patients with mild to moderate symptoms, and that it has a high success rate in controlling the virus in their bodies.
The U.S. Food and Drug Administration says the new vaccine can protect against three types of coronaviruses: Acute, Chronic, and Stage 4.
The company, Johnson & Johnson, says the vaccine is a mixture of antibodies that bind to the coronvirus and the virus itself.
The vaccine works in people who have mild to severe symptoms, but that doesn’t necessarily mean they’re going to be protected.
It only works if they are taking a daily dose of at least a 50-mcg dose.
The FDA says the company is using the vaccine to fight the spread of the coronaves in the United States.
The vaccine is being tested in more than 1,000 people, including patients with acute respiratory infections and patients who have severe symptoms.
The FDA says it will also test the vaccine in the people with milder symptoms and those who are healthy.
The approval comes after the FDA approved the vaccine for use last month.
In August, it also approved a drug that can prevent people with severe respiratory infections from catching the coronacids.
It also comes after another coronaviral vaccine, made by Merck &.; Co., was approved last month for use by patients with moderate to severe respiratory symptoms.
That vaccine has had mixed results.
The agency approved the drug in November for use to treat acute respiratory illness, but it has had a high failure rate of 80 percent in those who have been vaccinated.
The new vaccine is expected to be approved by the FDA this month.